• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » The COMBINE Study: A Core Paper in the Treatment of AUD

The COMBINE Study: A Core Paper in the Treatment of AUD

November 22, 2019
Brian Frankel, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Brian Frankel, MD Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Anton RF et al, JAMA 2006;295(17):2003–2017

Conducted from 2001 to 2004 and published in 2006, the COMBINE study was the largest pharmacotherapy study that assessed the treatment of alcohol use disorder (AUD). Although there were significant data on the use of naltrexone and acamprosate (both had been FDA approved), widespread use had not been adopted, and extended release naltrexone was still undergoing its approval process. The prior large NIAAA-funded study of AUD interventions was Project MATCH, which focused exclusively on psychosocial therapies, whereas COMBINE evaluated the effectiveness of naltrexone, acamprosate, and specialty therapy both alone and in combination. By doing so, the authors hoped to shed light on the following questions: 1) Are there synergistic intervention combinations? 2) Is effective treatment of AUD feasible in a primary care setting?

1383 recently abstinent subjects across 11 academic sites were randomly assigned to 9 groups, and the trial was conducted over 16 weeks. Outcomes included percent days abstinent and return to heavy drinking. Combined behavioral intervention (CBI), an amalgamation of the evidence-based therapies used in Project MATCH (cognitive behavioral therapy, 12-step facilitation, and motivational interviewing), is a specialty therapy developed for this study. One group received only CBI (no pills) and the 8 pill-taking groups received varying combinations of CBI, acamprosate, naltrexone, and placebo, including a placebo-only group. Those eight groups also received medical management (MM), a brief evaluative and supportive intervention with a health care professional similar to a primary care encounter.

Compared to placebo, naltrexone reduced the percentage of participants who returned to heavy drinking (68.2% vs 71.4%; p = 0.02), but not percent days abstinent (78.8% vs 77.2%; p = 0.25). In contrast, acamprosate did not separate from placebo in any condition or interaction. A more striking result, however, was how poorly the CBI-only group performed in comparison to the pill-taking + MM groups, including in comparison to the placebo groups. For instance, placebo groups produced significantly greater percent days abstinent than CBI alone (p < 0.001). Although the authors point out a statistically significant interaction between CBI and naltrexone, this was not very convincing, as the data for this interaction included subjects receiving placebo. For those who received actual naltrexone, the CBI + naltrexone group was no better than naltrexone alone.

CATR’s Take
This study demonstrates that evidence-based AUD treatment can be delivered in non-specialty settings, which would expand access tremendously. Although clearly not a panacea, naltrexone performed well in the MM model. Acamprosate did not fare well, and it may perform better when initiated after a longer period of abstinence. This was also a disappointing study for psychotherapy, but the findings aren’t enough reason to write it off, and the role of psychosocial interventions in addiction treatment was discussed in the prior issue of CATR.
Addiction Treatment
KEYWORDS acamprosate addiction addiction-treatment alcohol alcohol-use alcohol-use-disorder alcoholism medication naltrexone pharmacology psychotherapy research research-update substance-use substance-use-disorders therapy-during-medication-appointment therapy-with-med-management
    Brian Frankel, MD

    Exposure Therapy Efficacious for PTSD Co-Occurring With Alcohol Use Disorder

    More from this author
    www.thecarlatreport.com
    Issue Date: November 22, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Medical Issues in Addiction Practice, CATR, November/December 2019
    Primer: Physical Examination in Addiction Practice
    Screening and Prophylaxis of Infectious Diseases in Addiction Practice
    PrEP: Introduction to the Basics
    Perioperative Management of Patients on Buprenorphine Maintenance
    Exposure Therapy Efficacious for PTSD Co-Occurring With Alcohol Use Disorder
    Varenicline and Bupropion: Soaring Again With EAGLES?
    The COMBINE Study: A Core Paper in the Treatment of AUD
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.